#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hodgkin's disease recurrent C3 glomerulopathy Warm autoimmune haemolytic anaemia Glycogen storage disease type V Oropharyngeal squamous cell carcinoma Myotonic dystrophy Microvillous inclusion disease Marginal zone lymphoma recurrent Sexually transmitted disease Pulmonary alveolar haemorrhage Prophylaxis against transplant rejection Cutaneous calcification Thymic carcinoma Andersen-Tawil syndrome Bronchiectasis More trials…

    Learn about Rare Diseases

    Pleomorphic leiomyosarcoma – Diagnostics Combined immunodeficiency – Treatment Hereditary neuropathic amyloidosis – Basic Information Primary biliary cholangitis CADASIL – Basic Information Nodal marginal zone B-cell lymphoma – Diagnostics Congenital nephrogenic diabetes insipidus Pulmonary sarcoidosis – Trials in Disease Myelodysplastic syndrome – Life with Disease Myelodysplastic syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    CHOLINE ALFOSCERATE R2R01 Tofersen Indometacin Ph. Eur. Itepekimab Levocabastine Hydrochloride ZOREVUNERSEN SODIUM L-Tryptophan Peginterferon Alfa-2A Ciprofloxacin Losartan LTI-03 Levamisole Hydrochloride [18F]Fluoro-Peg-Folate Enfuvirtide Alisertib Sodium Sevoflurane Human Plasma Protein Fidanacogene Elaparvovec Progesterone Ph. Eur. More therapies…

    Learn about Your Condition

    Autism spectrum disorder Factor IX deficiency Psychological trauma Trisomy 21 Cerebral haemorrhage Familial hypertriglyceridaemia Peritoneal dialysis Papilloma viral infection Chronic disease Sleep disorder Haemorrhage prophylaxis IgA nephropathy Heparin resistance Head and neck cancer stage IV Epilepsy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Facioscapulohumeral muscular dystrophy

  • Study on the Effectiveness and Safety of Satralizumab for Patients with Type 1 Facioscapulohumeral Muscular Dystrophy

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Facioscapulohumeral muscular dystrophy
    Investigated Drugs:
    • Satralizumab
    France

  • Study on AOC 1020 for Adults with Facioscapulohumeral Muscular Dystrophy (FSHD)

    Not recruiting

    2 1
    Investigated Diseases:
    • Facioscapulohumeral muscular dystrophy
    Investigated Drugs:
    • Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dux4 Mrna Via A Non-Cleavable Linker
    Italy The Netherlands
Previous Page
1 2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!